Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Interest Expense
Cost of servicing the company's debt during the period.
Evommune, Inc.NYSE: EVMN
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense remains negative
Q1 FY2026 interest expense was $0, compared with $4K a year earlier. Trailing-twelve-month interest expense was $3K.
Context
- Interest expense amounted to 0.0% of revenue in FY2025, down 0.5 pp from a year earlier.
- Interest expense increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $750.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 34K | -41.4% |
| FY2023 | 2023-12-31 | 58K | — |
Interest Expense vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 interest expense of $3K is the 6th highest of the 10 companies compared; the peer median is $1.29M.
- Interest expense amounts to 0.0% of revenue for EVMN, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | LTM Jun 2026 | $84M | -6.5% | +670.3% | 3.1% |
| LTM Mar 2026 | $47.41M | +11.5% | +22.4% | 31.4% | |
| LTM Sep 2026 | $8.75M | — | — | 3.3% | |
| LTM Jun 2026 | $6.19M | +69.9% | +37.9% | 2.1% | |
| LTM Mar 2026 | $1.29M | +201.9% | — | 1.7% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $3K | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $0 | — | — | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding EVMN) | $1.29M | +11.5% | +37.9% | 2.1% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.